Literature DB >> 35737168

Cell division control protein 42 correlates with lower disease risk and its elevation predicts better treatment response, and inhibits T-helper 17 cell differentiation in rheumatoid arthritis.

Yameng Yang1, Li Huang2, Bin Wu3.   

Abstract

OBJECTIVE: Previous research reports that cell division control protein 42 (CDC42) is dysregulated in rheumatoid arthritis (RA). This study aimed to further explore the linkage of CDC42 with T-helper (Th) 1 and Th17 cell differentiation, and its implication in RA management.
METHODS: After enrolling 80 RA patients, their blood CDC42, Th1 and Th17 cells were detected by RT-qPCR and flow cytometry, respectively, IFN-γ and IL-17A were detected by ELISA. Based on the treatment response at week 12, the patients were classified as response patients and no response patients. In addition, blood CDC42 was also detected after enrolling 40 healthy controls. Subsequently, naïve CD4+ T cells from RA patients were transfected with control, CDC42 overexpression and knockdown lentivirus, followed by differentiation assay.
RESULTS: CDC42 was reduced in RA patients versus healthy controls (P < 0.001). In RA patients, CDC42 was negatively correlated with IFN-γ (P = 0.023), Th17 cells (P = 0.011) and IL-17A (P = 0.003) but not Th1 cells (P = 0.200). CDC42 presented an increasing trend after treatment (P < 0.001); besides, CDC42 at week 8 (P = 0.027) and week 12 (P < 0.001) were increased in response patients versus no response patients. Subsequent experiment showed that in RA CD4+ T cells, CDC42 overexpression reduced IFN-γ and IL-17A (both P < 0.05), while CDC42 knockdown elevated IL-17A (P < 0.05) but not IFN-γ (P > 0.05). Moreover, CDC42 overexpression inhibited, while CDC42 knockdown increased Th17 cell percentage (P < 0.05) but not Th1 cell percentage (P > 0.05).
CONCLUSIONS: CDC42 negatively correlates with disease risk and its elevation predicts better treatment response; it also inhibits Th17 but not Th1 cell differentiation in RA.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CDC42; Disease activity; Rheumatoid arthritis; Th cell differentiation; Treatment response

Year:  2022        PMID: 35737168     DOI: 10.1007/s10787-022-00979-z

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  2 in total

1.  Vascular endothelial Cdc42 deficiency delays skin wound-healing processes by increasing IL-1β and TNF-α expression.

Authors:  Mengying Xu; Jiawen Lv; Ping Wang; Yanxia Liao; Yiran Li; Wen Zhao; Junchao Zen; Zheyu Dong; Zihao Guo; Xiaoyin Bo; Min Liu; Lin Zhang; Guodong Hu; Yinghua Chen
Journal:  Am J Transl Res       Date:  2019-01-15       Impact factor: 4.060

2.  The relationship of blood CDC42 level with Th1 cells, Th17 cells, inflammation markers, disease risk/activity, and treatment efficacy of rheumatoid arthritis.

Authors:  Yongji Li; Wendi Yang; Feng Wang
Journal:  Ir J Med Sci       Date:  2021-12-02       Impact factor: 2.089

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.